Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Immune Pharmaceuticals to Take Over Epicept

Published: Friday, November 09, 2012
Last Updated: Friday, November 09, 2012
Bookmark and Share
The merged company will develop antibody therapeutics and other targeted drugs for the treatment of inflammatory diseases and cancer.

Immune Phamaceuticals Ltd. is taking over EpiCept Corporation in share swap deal. The merged company, Immune Pharmaceuticals Inc., will develop antibody therapeutics and other targeted drugs for the treatment of inflammatory diseases and cancer. The merger is due to close in the first quarter of 2013.

Immune Pharmaceuticals shareholders will own 77.5% of the merged company, and EpiCept shareholders will own 22.5%. The merged company will be headquartered in Herzliya Pituach and in Tarrytown, New York, and will have research laboratories in Rehovot. Immune Pharmaceuticals founder and CEO Dr. Daniel Teper will become the chairman and CEO of the merged company, and Dr. David Sidransky will become vice chairman.

Immune’s lead product candidate, bertilimumab, is a full human monoclonal antibody for the treatment of inflammatory diseases. It is undergoing a Phase II clinical trial for the treatment of ulcerative colitis. The merged company's oncology products will include Immune’s NanomAbs, a new generation of antibody drug conjugates, and EpiCept’s AmiKet, which is undergoing a Phase III clinical trial for the treatment of chemotherapy-induced neuropathic pain and post-herpetic neuralgia.

Teper and EpiCept interim president and CEO Robert Cook said in a statement, "This transaction will create a publicly traded specialty biopharmaceutical company with a portfolio of four clinical-stage drug candidates for the treatment of inflammatory diseases and cancer. Immune's bertilimumab, a first in class monoclonal antibody, is being evaluated clinically to address unmet medical needs in multiple severe disease indications. EpiCept's Amiket has clinical data in over 1,600 patients in various neuropathies, Fast Track designation and Phase III Special Protocol Assistance from the US Food and Drug Administration as well as a defined clinical path through the European Medicines Agency for the treatment of chemotherapy induced neuropathic pain."


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Immune Initiates Bertilimumab Phase II Clinical Trial in Ulcerative Colitis
Bertilimumab targets eotaxin-1, a chemokine over-expressed in ulcerative colitis patients.
Friday, February 22, 2013
Scientific News
Liquid Biopsies: Utilization of Circulating Biomarkers for Minimally Invasive Diagnostics Development
Market Trends in Biofluid-based Liquid Biopsies: Deploying Circulating Biomarkers in the Clinic. Enal Razvi, Ph.D., Managing Director, Select Biosciences, Inc.
Lab-on-a-Chip Offers Promise for TB and Asthma Patients
A device to mix liquids using ultrasonics is the first and most difficult component in a miniaturized system for low-cost analysis of sputum from patients with pulmonary diseases such as tuberculosis and asthma.
Intracellular Microlasers Could Allow Precise Labeling of up to a Trillion Individual Cells
MGH investigators have induced structures incorporated within individual cells to produce laser light at wavelengths that differ based on the size, shape and composition of each microlaser, allowing precise labeling of individual cells.
Real-Time Imaging of Lung Lesions During Surgery
Targeted molecular agents cause lung adenocarcinomas to fluoresce during surgery, according to pilot report.
Watching a Tumour Grow in Real-Time
Researchers from the University of Freiburg have gained new insight into the phases of breast cancer growth.
Protein Related to Long Term Traumatic Brain Injury Complications Discovered
NIH-study shows protein found at higher levels in military members who have suffered multiple TBIs.
Childhood Cancer Cells Drain Immune System’s Batteries
Cancer cells in neuroblastoma contain a molecule that breaks down a key energy source for the body’s immune cells, leaving them too physically drained to fight the disease.
Urine Proteins Point to Early-Stage Pancreatic Cancer
A combination of three proteins found at high levels in urine can accurately detect early-stage pancreatic cancer, researchers at the BCI have shown.
Researcher Discovers Trigger of Deadly Melanoma
New research sheds light on the precise trigger that causes melanoma cancer cells to transform from non-invasive cells to invasive killer agents, pinpointing the precise place in the process where "traveling" cancer turns lethal.
New Vaccine For Chlamydia to Use Synthetic Biology
Prokarium Ltd, a biotechnology company developing transformational oral vaccines, have announced new funding from SynbiCITE, the UK’s Innovation and Knowledge Centre for Synthetic Biology.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!